Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2295 SEK | +20.54% | +13.61% | -97.70% |
05-10 | Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar | MT |
05-02 | Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.70% | 32.39M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma, Stada Jointly Launch Lucentis Biosimilar in Germany